Legal & General Group Plc Acquires New Shares in Lantheus Holdings, Inc. $LNTH

Legal & General Group Plc acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 88,207 shares of the medical equipment provider’s stock, valued at approximately $9,786,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Western Wealth Management LLC acquired a new position in shares of Lantheus in the 1st quarter valued at $25,000. Smartleaf Asset Management LLC increased its position in shares of Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares during the last quarter. Parallel Advisors LLC increased its position in shares of Lantheus by 122.6% during the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 298 shares during the last quarter. Osterweis Capital Management Inc. purchased a new stake in Lantheus in the 2nd quarter valued at about $36,000. Finally, Bessemer Group Inc. raised its holdings in Lantheus by 221.2% in the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 354 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

NASDAQ LNTH opened at $100.96 on Tuesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. The company has a market cap of $6.59 billion, a P/E ratio of 24.39 and a beta of -0.03. The stock has a 50-day moving average of $103.64 and a two-hundred day moving average of $92.00. Lantheus Holdings, Inc. has a 1-year low of $49.67 and a 1-year high of $111.86.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business had revenue of $388.18 million for the quarter, compared to analysts’ expectations of $363.23 million. During the same quarter in the prior year, the company earned $1.57 earnings per share. The business’s quarterly revenue was up 2.7% on a year-over-year basis. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 4.48 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. CJS Securities lowered shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research note on Tuesday, August 4th. TD Cowen downgraded shares of Lantheus from a “buy” rating to a “hold” rating and reduced their price target for the company from $110.00 to $102.50 in a research note on Monday, August 3rd. Citigroup restated an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Weiss Ratings raised shares of Lantheus from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday. Finally, Truist Financial downgraded shares of Lantheus from a “buy” rating to a “hold” rating and dropped their target price for the company from $125.00 to $102.50 in a report on Monday, August 3rd. Four equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $108.11.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.